Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tadekinig alfa
- Development stage
- Phase 3
- Lead developer
- AB2 Bio
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Subcutaneous
01
Overview
Tadekinig alfa is a recombinant human interleukin-18 (IL-18) binding protein that acts by specifically binding to and neutralizing IL-18, a pro-inflammatory cytokine implicated in several rare systemic inflammatory conditions. By restoring the balance between IL-18 and its natural inhibitor, Tadekinig alfa reduces pathological inflammation associated with diseases such as macrophage activation syndrome (MAS), hemophagocytic lymphohistiocytosis (HLH), NLRC4-macrophage activation syndrome (NLRC4-MAS), XIAP deficiency, adult-onset Still's disease (AoSD), and systemic juvenile idiopathic arthritis (sJIA). The drug is administered subcutaneously and has demonstrated favorable safety and efficacy profiles in clinical trials. Tadekinig alfa has received orphan drug designations in both the US and Europe for these indications[1][3][5][6][7].
- Other names
- recombinant IL-18 binding proteinr-hIL-18BPr-hIL18BPr-hIL 18BP
02
Targets
IL18 (Interleukin-18)
Beyond the preview
Go deeper on tadekinig alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tadekinig alfa.